Background: Up until now, the optimal strategy for postoperative pain management after
total knee arthroplasty (TKA) remains to be elucidated.
Objective: The current investigation aimed to examine the analgesic efficacy and the
opioid sparing effects of intravenous parecoxib in combination with continuous femoral
blockade.
Study Design: Randomized, double-blind, prospective trial.
Setting: University hospital in the United Kingdom.
Methods: In total, 90 patients underwent TKA under subarachnoid anesthesia and
received continuous femoral block initially as a bolus with 20 mL of ropivacaine 0.75%.
Infusion of 0.2% on 10 mL/h followed. Patients were randomized into 2 groups. Group D
and Group P received parecoxib and placebo, respectively at 12 hour time intervals. Visual
analog scale (VAS) pain scores were obtained at different time intervals including 4, 8, 12, 24
and 36 hours. The pain scores were measured with patients in a resting position. Morphine
could also be administered with a patient controlled analgesia (PCA) pump if the specified
analgesia was deemed inadequate (VAS > 5).
Results: None of the patients were withdrawn from the study. Parecoxib provided greater
relief than placebo following TKA. The VAS pain scores measured at rest were statistically
significantly lower in parecoxib-treated patients compared to the placebo group (P = 0.007)
at 4 (P = 0.044), 12 (P = 0.001), and 24 hours (P = 0.012), postoperatively. Patients receiving
parecoxib consumed less morphine at all time intervals than patients receiving placebo,
with borderline statistical significance (P = 0.054). In each time period, all patients receiving
continuous femoral block irrespectively of the treatment group, required low morphine
doses.
Limitations: Current protocol did not answer question as to functional recovery.
Conclusion: According to our findings intravenous parecoxib in combination with
continuous femoral block provided superior analgesic efficacy and opioid sparing effects in
patients undergoing TKA.
Key words: Anesthesia, TKA, morphine, opioids, VAS scores, continuous femoral block
Introduction
Intravenous administration of parecoxib could provide significant pain relief in surgical operations that require additional forms of analgesia. However, very little is known about its effects on the anxiety levels of patients before a surgical procedure. The aim of this prospective study was to investigate whether intravenous parecoxib, pre-emptively administered, has an effect on anxiety levels experienced post-surgically after total knee arthroplasty (TKA) and if it influences the reported pain of the procedure itself.
Methods
A total of 90 patients who underwent TKA under spinal anesthesia were included in the study. Prior to TKA, all patients received continuous femoral nerve block (CFNB) and were randomized into two groups: Group D consisted of 45 patients who received the drug parecoxib intravenously in addition to CFNB, whereas Group P consisted of 45 patients who received a placebo drug (N/S 0.9 %) intravenously instead of parecoxib. All patients were asked to fill in the questionnaires STAI1 and STAI2 in order to evaluate anxiety levels pre- and post-surgically, respectively. One of the main aims was to distinguish personality-trait anxiety from state anxiety, i.e., anxiety experience due to the actual perioperative events and the actual pain endured.
Results
The group receiving parecoxib had statistically significant lower anxiety levels both for personality trait anxiety and state anxiety, as compared to the placebo group.
Conclusions
Based on our findings, parecoxib had both analgesic and anxiolytic effects in patients undergoing TKA with CFNB.
Trial Registration
Current Controlled Trials: NCT02185924.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.